Injection site reactions, mostly mild in severity, were reported in 5.2 percent of patients in the romosozumab treatment group and 2.9 percent in the placebo group during the 12-month period.

Romosozumab use in adults with osteoporosis was associated with a 21% reduction in risk for osteoarthritis, particularly knee osteoarthritis, compared with teriparatide use. Researchers used a ...

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial. The findings were ...

In postmenopausal women with osteoporosis, prior fracture, and type 2 diabetes, 12 months of romosozumab significantly improved bone strength when combined with alendronate, compared with alendronate ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Romosozumab is a US Food and Drug Administration-approved humanized monoclonal antibody used to treat osteoporosis in postmenopausal women with a high risk for fracture. The study included 70 adults ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...